CMBI Anticipates Ongoing Trend in Innovative Drug Exports, Assigns Buy Ratings to SINO BIOPHARM, WUXI XDC, and Others
Performance of MSCI China Health Care Index: The MSCI China Health Care Index has increased by 11.8% year-to-date, surpassing the MSCI China Index's growth of 9.1%, as reported by CMBI.
Factors Driving Pharmaceutical Growth: The rise in the pharmaceutical sector is attributed to a valuation adjustment in Q4 2025 and increased interest from institutional investors at the start of the year.
Future Outlook for Innovative Drugs: The trend of innovative drug exports is anticipated to persist into 2026, with clinical advancements and overseas pipeline data being crucial for growth.
CMBI Ratings on Pharmaceutical Stocks: CMBI has assigned "Buy" ratings to several pharmaceutical companies, including 3SBIO, GUSHENGTANG, WUXI XDC, and SINO BIOPHARM, with detailed ratings and target prices available in a separate table.
Trade with 70% Backtested Accuracy
Analyst Views on 01177
About the author

Stock Performance: Several pharmaceutical stocks showed mixed performance, with HENGRUI PHARMA and HANSOH PHARMA experiencing gains, while SINO BIOPHARM saw a decline.
Short Selling Data: Short selling activity varied across companies, with SINO BIOPHARM having the highest short selling amount at $180.02M and a ratio of 40.682%.
Target Prices: Analysts have set target prices for various stocks, with HENGRUI PHARMA and HANSOH PHARMA rated as "Buy" with target prices of HK$98.3 and HK$51.5, respectively.
Market Sentiment: CSPC PHARMA received a "Neutral" rating, indicating a more cautious outlook compared to the "Buy" ratings for other companies listed.

Hong Kong Stock Market Performance: The Hong Kong stock market opened higher but closed lower, with the HSI down 384 points (1.4%) at 26,381, and total market turnover at HKD259.277 billion.
CKI Holdings' Stock Surge: A consortium led by CKI Holdings sold UKPN, resulting in a 4.5% increase in its stock price, while CKH Holdings and Power Assets also saw significant gains.
Tech Sector Declines: Alibaba's stock fell 3.6% after a report predicted weak quarterly profits, while other tech stocks like Tencent and Meituan also experienced declines.
Pharmaceuticals and Consumer Stocks Drop: Various pharmaceutical and consumer stocks saw significant losses, with declines ranging from 3.3% to 9.2% across multiple companies.

Market Performance: The HSI fell by 491 points (1.8%) to 26,590, with the HSCEI and HSTECH also experiencing declines of 2.1%, closing at 9,007 and 5,270 respectively, amid a total market turnover of HKD250.992 billion.
Tech Stock Declines: Major tech stocks like TENCENT, BABA-W, and MEITUAN-W saw significant drops, with short selling ratios indicating high market activity, reflecting a broader downturn in the tech sector.
Pharmaceutical Sector Struggles: Pharmaceutical stocks continued to decline, with CSPC PHARMA and SINO BIOPHARM among the biggest losers, as short selling activity remained high in this sector.
Financial Sector Highlights: STANCHART reported a 3.1% increase in stock price after announcing a significant rise in dividend distribution, contrasting with the overall negative trend seen in Chinese insurers, which experienced declines.

Market Performance: The Hang Seng Index (HSI) fell by 491 points (1.8%) to close at 26,590, with significant declines also seen in the HSTI and HSCEI, which dropped 114 points (2.1%) and 189 points (2.1%) respectively, amid a market turnover of $250.99 billion.
Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, Alibaba, and Xiaomi experienced notable declines, with Meituan down 4.2% and Tencent down 3.3%, reflecting a trend of short selling across these companies.
Constituents on the Move: Several constituents saw significant price changes, including Sino Biopharma and Hansoh Pharma, which dropped 6.6% and 6.4% respectively, while WH Group rose by 4.4%, reaching a new high.
Other Notable Stocks: Stocks such as MIRXES-B and CTG Duty-Free faced substantial losses, with MIRXES-B down 21.7%, while KB Laminates and CNBM saw gains of 12.4% and 10.5%, respectively, also hitting new highs.

Market Performance: The HSI fell 523 points (1.9%) to 26,558, with the HSCEI down 190 points (2.1%) and the HSTECH dropping 127 points (2.4%), amid a total turnover of HKD138.679 billion.
Tech Stocks Decline: Major tech stocks like TENCENT, BABA-W, and MEITUAN-W experienced significant declines, with short selling ratios indicating increased bearish sentiment.
AI and Robotics Sector Struggles: Stocks in the AI sector, including SENSETIME-W and PHANCY, saw substantial losses, while robotics stocks like DOBOT plunged over 10%.
Pharmaceutical and Insurance Stocks Down: Pharma stocks such as CSPC PHARMA and Chinese insurers like CHINA LIFE faced declines of 4-6%, reflecting a broader downturn in these sectors.

Market Performance: The Hang Seng Index (HSI) fell by 523 points (1.9%) to 26,558, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 2.4% and 2.1%, respectively.
Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, and Alibaba saw significant drops, with Meituan down 4.8% and Tencent down 3.4%, amidst high short selling ratios.
Notable Declines in Constituents: Several constituents, including Hansoh Pharma and Sino Biopharma, reported steep declines, with Hansoh Pharma down 6.5% and Sino Biopharma down 6.1%.
Gainers Amidst Losses: Despite the overall market downturn, a few stocks like WH Group and Henderson Land recorded gains, with WH Group up 3.2% and Henderson Land up 1.7%, both hitting new highs.






